UBX - Unity Biotechnology: One Last Chance With UBX1325
2023-03-05 07:14:56 ET
Summary
- Shares of ophthalmology concern Unity Biotechnology are down some 90% since our last look in March 2021 as a news vacuum following a failed Phase 2 trial in October.
- That said, the company was able to leverage good interim data from its only clinical asset in August 2022 into a cash runway extending capital raise.
- With a huge market opportunity and a $65 million market cap against a changing competitive landscape, this busted IPO merited another look.
- A full investment analysis and recommendation follow in the paragraphs below.
For further details see:
Unity Biotechnology: One Last Chance With UBX1325